The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment:

Published on Feb 19, 2019in Tumori1.707
· DOI :10.1177/0300891619829571
Marco Siano12
Estimated H-index: 12
(HSG: University of St. Gallen),
Salvatore Alfieri14
Estimated H-index: 14
+ 4 AuthorsLaura D. Locati31
Estimated H-index: 31
Source
Abstract
Purpose:Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when an...
📖 Papers frequently viewed together
11 Citations
8 Citations
71 Citations
References10
Newest
#1Martin Schlumberger (Université Paris-Saclay)H-Index: 115
#1M. SchlumbergerH-Index: 57
Last. Steven I. Sherman (University of Texas MD Anderson Cancer Center)H-Index: 86
view all 19 authors...
Background:Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was carried out after long-term follow-up. Patients and methods:EXAM compared cabozantinib with placebo in 330 patients with docume...
55 CitationsSource
#1R. Michael Tuttle (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 77
#2Marcia S. Brose (UPenn: University of Pennsylvania)H-Index: 45
Last. Mona M. Sabra (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 19
view all 6 authors...
Multitargeted kinase inhibitors have been shown to improve progression-free survival in patients with structurally progressive, radioactive iodine refractory differentiated thyroid cancer. While the inclusion criteria for phase 3 clinical trials and clinical practice guidelines provide guidance with regard to the minimal requirements that need to be met prior to initiation of a multitargeted kinase inhibitor, a better way to integrate the rate of structural disease progression with the size of t...
17 CitationsSource
#1Steven I. Sherman (University of Texas MD Anderson Cancer Center)H-Index: 86
#2Douglas O. Clary (Exelixis)H-Index: 29
Last. Marcia S. Brose (UPenn: University of Pennsylvania)H-Index: 45
view all 10 authors...
BACKGROUND Cabozantinib significantly prolonged progression-free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P < .001). An exploratory analysis of phase 3 trial data evaluated the influence of rearranged during transfection (RET) and RAS (HRAS, KRAS, and NRAS) mutations on cabozantinib clinical activity. METHODS Patients (n = 330) were randomized to cabozantinib (140 mg/day) or a placebo. The primary endpoint was PFS. Additional outcome...
42 CitationsSource
#1Andrew G. Gianoukakis (UCLA: University of California, Los Angeles)H-Index: 21
#2Natalia M. FloresH-Index: 2
Last. Matthew H. TaylorH-Index: 31
view all 6 authors...
Background Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse.
7 CitationsSource
#1Sook Fen Ong (Gosford Hospital)H-Index: 1
#2Michael Harden (RNSH: Royal North Shore Hospital)H-Index: 2
Last. Richard Wai Wing Lee (Gosford Hospital)H-Index: 1
view all 4 authors...
Spontaneous regression of metastatic melanoma is a rare event with only 76 cases having been reported since 1866. The precise mechanism of regression remains unknown. We present a case of a man with spontaneous regression of pulmonary metastatic melanoma confirmed on histopathology accompanied by reduction in fluorodeoxyglucose-activity on serial positron emission tomography/computed tomography scan.
5 CitationsSource
#1Samuel A. Wells (NIH: National Institutes of Health)H-Index: 77
#2Sylvia L. Asa (U of T: University of Toronto)H-Index: 114
Last. Steven G. WaguespackH-Index: 44
view all 18 authors...
Introduction: The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association. Methods: The Task Force identified relevant articles using a systematic PubMed search, supplemented with additional published materials, and then created evidence-based recommendations, which were set in categories using criteria adapted from the United States Preventive Services Task Force Agency for Healt...
817 CitationsSource
#1Rossella Elisei (UniPi: University of Pisa)H-Index: 83
#2Martin Schlumberger (UniPi: University of Pisa)H-Index: 115
Last. Steven I. Sherman (UniPi: University of Pisa)H-Index: 86
view all 19 authors...
Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I. Patients and Methods We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to c...
635 CitationsSource
#1Samuel A. Wells (NIH: National Institutes of Health)H-Index: 77
#2Bruce G. Robinson (Kolling Institute of Medical Research)H-Index: 86
Last. Martin Schlumberger (Institut Gustave Roussy)H-Index: 115
view all 14 authors...
Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.
887 CitationsSource
#1Elizabeth A. Eisenhauer (Queen's University)H-Index: 69
#2P. Therasse (GSK: GlaxoSmithKline)H-Index: 13
Last. Jaap Verweij (Erasmus University Medical Center)H-Index: 125
view all 16 authors...
Abstract Background Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to th...
16.4k CitationsSource
#1Michael J. Edwards (University of Louisville)H-Index: 71
#2James A. Anderson (University of Louisville)H-Index: 6
Last. James I. Harty (University of Louisville)H-Index: 14
view all 4 authors...
Spontaneous regression of metastases in renal cell carcinoma has been occasionally described since the first report in 1928 by Bumpus.' The majority of cases involve regression of pulmonary metastases after removal of the primary tumor.2-4 We report a case in which pulmonary metastases and the primary renal tumor regressed in association with significant hemorrhage at the time of biopsy. CASE REPORT
22 CitationsSource
Cited By1
Newest
Hintergrund Das medullare Schilddrusenkarzinom („medullary thyroid carcinoma“, MTC) macht etwa 10 % aller Schilddrusenkarzinome aus und tritt sporadisch, familiar und im Rahmen einer multiplen endokrinen Neoplasie (MEN) Typ 2 auf. Bildgebende Verfahren spielen eine zentrale Rolle beim Screening in betroffenen Familien sowie in der Diagnostik.
2 CitationsSource